EU/3/07/470

Table of contents

About

On 14 September 2007, orphan designation (EU/3/07/470) was granted by the European Commission to Cytonet GmbH & Co. KG, Germany, for human heterologous liver cells (for infusion) for the treatment of ornithine-transcarbamylase deficiency

A marketing authorisation for this medicine (Heparesc) was refused on 22 October 2015.

The sponsorship was transferred to Promethera Biosciences, Belgium, in June 2016.

Key facts

Active substance
Human heterologous liver cells (for infusion)
Disease / condition
Treatment of ornithine-transcarbamylase deficiency
Date of decision
14/09/2007
Outcome
Positive
Orphan decision number
EU/3/07/470

Sponsor's contact details

Promethera Biosciences
11 Rue Granbonpré
1435 Mont-Saint-Guibert
Belgium
Tel. +32 (0)10 394 304
Fax +32 (0)10 394 301
E-mail: contact@promethera.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating